In many developed countries, including the U.S. and Australia, DTaP (diphtheria, tetanus, and acellular pertussis) replaced DTwP (diphtheria, tetanus, and whole-cell pertussis) in the 1990s because it carried a lower risk of such adverse events as injection-site reactions and fever.